Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    AHA Recommends Routine Depression Screening for Patients With Heart Disease - (DGNews)
    Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis - (JAMA)
    Criteria Identified to Predict Nonsurvival of Extrahospital Cardiac Arrest - (DGNews)
    Anticholinergics May Increase Risk of Cardiovascular Death, MI, or Stroke in COPD Patients - (DGNews)
    Aldosterone Receptor Antagonists Do Not Reduce Defibrillator Shocks: Presented at HFSA - (DGDispatch)

    News archive

     Recent webcasts/CME - Cardiology Other
      Global CV Risk Management: Is it Practical?
      Cardiovascular Disease in Patients With Rheumatoid Arthritis: Results From the QUEST-RA Study
      Impact of Insulin Resistance on Cardiometabolic Risk
      Reducing Cardiovascular Morbidity and Mortality Through RAAS Modulation: New Trial Data
      Adiposity in Cardiovascular Risk Reduction

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Lithium Intoxication Related Multiple Temporary ECG Changes : A Case Report
        Isolated Left Ventricular Non-Compaction as an Unusual Cause of Heart Failure: A Case Report
        Pancytopenia and Atrial Fibrillation Associated with Chronic Hepatitis C Infection and Presumed Hepatocellular Carcinoma: A Case Report
        An Echocardiographic-Confirmed Case of Atrial Myxoma Causing Cerebral Embolic Ischemic Stroke: A Case Report
        Brugada Syndrome During Physical Therapy: A Case Report

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Sertraline May Enhance Antiplatelet Activity in Patients With Acute Coronary Syndromes

        A DGReview of :"Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events. The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy"
        Circulation

        08/19/2003
        By Emma Hitt, PhD


        The selective serotonin reuptake inhibitor (SSRI) sertraline may benefit patients with acute coronary syndromes (ACS) because of its anti-platelet activity.

        According to Victor L. Serebruany MD, PhD, with the Sinai Center for Thrombosis Research at Johns Hopkins University, Baltimore, United States, and colleagues, enhanced platelet activation is thought to be one of the mechanisms underlying the association between depression after acute coronary syndromes. In addition, SSRIs are known to inhibit platelet activity.

        The researchers assessed the release of established platelet/endothelial biomarkers in patients treated with sertraline versus placebo in the Sertraline AntiDepressant Heart Attack Randomised Trial (SADHART).

        Participants were randomised to sertraline (n=28) or placebo (n=36) and plasma samples were collected at baseline, week 6, and week 16. Various markers of platelet/endothelial biomarkers were measured, including platelet factor 4, and beta-thromboglobulin. Patients were allowed to take anticoagulants, aspirin, and ADP-receptor inhibitors.

        Treatment with sertraline was associated with a decreased release of platelet/endothelial biomarkers compared to treatment with placebo. These differences were significant for beta-thromboglobulin (p=0.03) at weeks 6 and 16 and P-selectin (p=0.04) at week 16.

        "Repeated-measures ANOVA revealed a significant advantage for sertraline versus placebo for diminishing E-selectin and beta-thromboglobulin concentrations across the entire treatment period," the researchers note.

        They point out that even though some patients were taking antiplatelet regimens including aspirin and ADP-receptor blockers, treatment with sertraline in depressed post-ACS patients was still associated with decreased platelet activation.

        "Thus, anti-platelet properties of sertraline differ from those of aspirin, dipyridamole, clopidogrel, and glycoprotein IIb/IIIa inhibitors, the pathways of which are well identified."

        They suggest that sertraline may initially target platelet serotonin receptors and then indirectly affect major platelet functions, such as adhesion, aggregation, secretion, or receptor expression.

        According to the researchers, "antiplatelet properties of SSRIs might represent an attractive additional advantage for patients with depression and comorbid coronary artery disease and ischaemic stroke."
        Circulation 2003 Aug 11;[Epub ahead of print]. "Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events. The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send